Table 6 |
||||||
|
Outcomes of study patients |
||||||
|
Intention to treat |
Modified intention to treat |
|||||
|
Antibiotic treatment n = 22 |
No antibiotic treatment n = 36 |
P value |
Antibiotic treatment n = 18 |
No antibiotic treatment n = 26 |
P value |
|
|
|
||||||
|
Duration of mechanical ventilation, days |
29 ± 17 |
26 ± 15 |
0.816 |
26 ± 15 |
24 ± 15 |
0.952 |
|
Mechanical ventilation-free days, median (interquartile range) |
12 (8–24) |
2 (0–6) |
<0.001 |
16 (9–25) |
4 (2–10) |
0.001 |
|
Length of ICU stay, days |
40 ± 23 |
36 ± 21 |
0.558 |
37 ± 21 |
33 ± 20 |
0.445 |
|
Ventilator-associated pneumonia |
3 (13) |
17 (47) |
0.011a |
2 (11) |
12 (46) |
0.021a |
|
ICU mortalityb |
4 (18) |
17 (47) |
0.047a |
0 (0) |
11 (42) |
0.001a |
|
Infection or colonization related to MDR bacteria |
9 (40) |
13 (36) |
0.784 |
7 (38) |
8 (30) |
0.748 |
|
Ceftazidime or imipenem-resistant Pseudomonas aeruginosa |
3 (13) |
6 (16) |
0.534 |
3 (16) |
5 (19) |
>0.999 |
|
Acinetobacter baumannii |
0 (0) |
2 (5) |
0.521 |
0 (0) |
0 (0) |
NA |
|
Stenotrophomonas maltophilia |
1 (4) |
0 (0) |
0.379 |
1 (5) |
0 (0) |
0.409 |
|
Methicillin-resistant Staphylococcus aureus |
2 (9) |
1 (2) |
0.551 |
1 (5) |
0 (0) |
0.409 |
|
ESBL-producing Gram-negative bacilli |
3 (13) |
4 (11) |
0.540 |
2 (11) |
3 (11) |
>0.999 |
|
|
||||||
|
Results of univariate analysis are presented. Data are expressed as frequency (percentage) or mean ± standard deviation unless otherwise indicated. aOdds ratios (95% confidence intervals) are 0.17 (0.04 to 0.70), 0.14 (0.02 to 0.76), 0.24 (0.07 to 0.88), and 0.45 (0.31 to 0.66), respectively. bPredicted mortality rates, based on Simplified Acute Physiology Score II at ICU admission, were 39%, 39%, 35%, and 41% in the four groups, respectively. ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; MDR, multidrug-resistant; NA, not applicable. |
||||||
|
Nseir et al. Critical Care 2008 12:R62 doi:10.1186/cc6890 |
||||||
